RPRX (Royalty Pharma) Price-to-Funds-From-Operations: (As of Sep. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RPRX Royalty Pharma PLC RPRX
72 GF Score
Price $63.98
GF Value $42.30
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

RPRX
72GF Score
Royalty Pharma PLC RPRX
Price-to-Funds-From-Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Royalty Pharma (RPRX) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of $63.98 is trading 51.2% above its estimated GF Value™ of $42.30. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for RPRX:

  • Price-to-Funds-From-Operations:
  • GF Value™: $42.30 vs. price of $63.98 (51.2% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the RPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score

Get the complete analysis for RPRX

Price-to-Funds-From-Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$63.98
Price
$42.30
GF Value